Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis

[Background & Aims] Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are associated with adverse clinical outcomes, impaired health-related quality of life, and significant economic burden. The growing burden of MASLD and MASH has led to the publication...

ver descrição completa

Detalhes bibliográficos
Autores: Younossi, Zobair M., Zelber-Sagi, Shira, Lazarus, Jeffrey V., Wong, Vincent Wai-Sun, Yilmaz, Yusuf, Duseja, Ajay, Eguchi, Yuichiro, Castera, Laurent, Pessoa, Mário Guimarães, Oliveira, Claudia Pinto, El-Kassas, Mohamed, Tsochatzis, Emmanuel, Fan, Jian-Gao, Spearman, C Wendy, Tacke, Frank, Castellanos Fernandez, Marlen Ivon, Alkhouri, Naim, Schattenberg, Jörn M., Romero-Gómez, Manuel, Noureddin, Mazen, Allen, Alina M., Ong, Janus P., Roberts, Stuart K., Shubrook, Jay H., Burra, Patrizia, Kohli, Rohit, Kautz, Achim, Holleboom, Adriaan G., Lam, Brian, Isaacs, Scott, Macedo, Paula, Gastaldelli, Amalia, Henry, Linda, Ivancovsky-Wajcman, Dana, Nader, Fatema, de Avila, Leyla, Price, Jillian K., Mark, Henry E., Villota-Rivas, Marcela, Barberá, Aurora, Kalligeros, Markos, Gerber, Lynn H., Alqahtani, Saleh A.
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2025
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/405954
Acesso em linha:http://hdl.handle.net/10261/405954
https://api.elsevier.com/content/abstract/scopus_id/105014987580
Access Level:Acceso aberto
Palavra-chave:Global
Guideline
MASH
MASLD
Descrição
Resumo:[Background & Aims] Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are associated with adverse clinical outcomes, impaired health-related quality of life, and significant economic burden. The growing burden of MASLD and MASH has led to the publication of a large number of MASLD/MASH guidelines by national and international societies. However, important differences among the recommendations have created confusion, contributing to a low implementation rate and suboptimal management of MASLD and MASH. Creating a consensus recommendation has become more important since the approval of a selective agonist of thyroid hormone β receptor (resmetirom) for MASH treatment in the United States. We built a consensus among the most recently published recommendations for MASLD/MASH.

Registros relacionados